Találati lista | Tudóstér

001-es BibID:	BIBFORM007089
Első szerző:	Szamosi Szilvia (belgyógyász, reumatológus)
Cím:	Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis : risk factors for accelerated macrovascular damage? / Szamosi, S., Csiki, Z., Szomjak, E., Szolnoki, E., Szoke, G., Szekanecz, Z., Szegedi, G., Shoenfeld, Y., Szucs, G.
Dátum:	2009
ISSN:	1080-0549 (Print)
Megjegyzések:	The purpose of this study was to investigate plasma homocysteine (Hcy) levels in patients with systemic sclerosis (SSc) and to study the association between plasma Hcy, C677T polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR), and the clinical manifestations in SSc. Associations of Hcy level, C677T MTHFR polymorphism, and macrovascular diseases were investigated in 152 patients with SSc and 58 controls. No significant differences in Hcy levels and MTHFR genotypes were found in SSc patients compared to controls or in SSc patients with limited cutaneous compared to diffuse disease. Significantly higher Hcy concentration was observed in patients with macroangiopathy/thromboembolic events compared to patients without such clinical manifestations (p < 0.05). There was significant correlation between age and macrovascular disorders, between Hcy level and the disease duration (r = 0.164; p < 0.05). Seventy-one percent of patients with macrovascular disorders had MTHFR polymorphism. In addition, 45% of patients with hyperhomocysteinemia had pulmonary hypertension. The presence of MTHFR C677T mutation influences the incidence of macrovascular abnormalities in SSc patients. Elevated Hcy levels may be associated with disease duration and the evolution of macrovascular disorders and pulmonary hypertension in SSc.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Female egyetemen (Magyarországon) készült közlemény Genetic Predisposition to Disease Homocysteine Humans Hypertrophy, Right Ventricular Male Methylenetetrahydrofolate Reductase (NADPH2) Middle Aged Polymorphism, Single Nucleotide Pulmonary Fibrosis Risk Factors Scleroderma, Systemic Thromboembolism Time Factors
Megjelenés:	Clinical Reviews in Allergy and Immunology. - 36 : 2-3 (2009), p. 145-9. -
További szerzők:	Csiki Zoltán (1962-) (belgyógyász, allergológus, klinikai immunológus, reumatológus) Szomják Edit (1961-) (belgyógyász) Szolnoki Erzsébet Szőke Gabriella Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:	elektronikus változat DOI elektronikus változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM001205
035-os BibID:	PMID:17916982
Első szerző:	Tarr Tünde (belgyógyász, allergológus és klinikai immunológus)
Cím:	Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies : a 5-year follow-up / Tünde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pál Soltész, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss
Dátum:	2007
Megjegyzések:	Objective: To analyze the association of antiphospholipid antibodies (aPL) with the development of clinical thrombotic manifestations and to characterize the efficacy of anti-thrombotic therapies used. Methods: 272 systemic lupus erythematosus (SLE) patients participated in the study. Patient files and a cumulative database were used to collect patients' medical histories. Anti-cardiolipin (aCL), anti-beta2-glycoprotein I (a??2GPI) antibodies, and lupus anticoagulant (LAC) were measured according to international recommendations. New thrombotic events were registered during follow-up. Results: The patients were prospectively studied for 5 years, of whom 107 were aPL negative (aPL- group). Criteria for antiphospholipid syndrome (APS) were fulfilled by 84 of 165 aPL-positive patients (APS+ group) indicating that SLE patients with aPL have around 50% risk to develop thrombotic complications. The aPL+ group (n?ë♯n81) consisted of aPL+ but APS- patients. LAC was the most common aPL (n?ë♯n27, 32.1%) in patients with APS. The cumulative presence of aPL further increased the prevalence of thrombotic events. During the follow-up period, aPL developed in 8 of 107 patients (7.5%) from the aPL- group, of whom 3 (2.8%) presented with thrombotic complications. Other types of aPL developed in 7 of 165 (4.2%) aPL+ patients within 5 years. New thrombotic events occurred in 3.7% of aPL+ (n?ë♯n3) and 8.3% (n?ë♯n7) of the APS group. During follow-up, 52 of 81 aPL+ patients received primary prophylaxis, and 1 (1.9%) had transient ischemic attack (TIA). In the non-treatment group, 2 (6.9%) had stroke. Seventy-nine of 84 of the APS patients received secondary prophylaxis, and myocardial infarction occurred in 2 patients (on cumarine therapy maintaining an international normalized ratio around 2.5-3.0), and 5 suffered a stroke/TIA (1 on aspirin and 4 on aspirin+cumarine). Conclusion: The findings emphasize the importance of determining both aCL and a??2GPI antibodies and LAC in SLE patients and the need for adequate anticoagulant therapy. ?? Humana Press Inc. 2007.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban SLE antiphospholipid antibodies thrombotic manifestation APS Follow-up LAC Primary prophylaxis acetylsalicylic acid antithrombocytic agent beta2 glycoprotein 1 antibody cardiolipin antibody coumarin lupus anticoagulant phospholipid antibody adult antiphospholipid syndrome article cerebrovascular accident cohort analysis controlled study data base deep vein thrombosis disease association disease course drug efficacy female follow uphigh risk population history of medicine human international normalized ratio lung embolism major clinical study male medical record prevalence prophylaxis prospective study stroke systemic lupus erythematosus thrombosis transient ischemic attack Adult Antibodies, Antiphospholipid Antibody Specificity Anticoagulants Antiphospholipid Syndrome Aspirin Cohort Studies Female Follow-Up Studies Humans Lupus Erythematosus, Systemic Male Middle Aged Thrombosis Time Factors egyetemen (Magyarországon) készült közlemény
Megjelenés:	Clinical Review of Allergy Immunology 32 : 2 (2007), p. 131-137. -
További szerzők:	Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Soltész Pál (1961-) (belgyógyász, kardiológus) Shoenfeld, Yehuda Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI Szerző által megadott URL
Borító:
Saját polcon: